Gabriel V Fontaine1, Katy D Mathews2, Scott C Woller3, Scott M Stevens3, James F Lloyd4, R Scott Evans4. 1. Department of Pharmacy, Intermountain Medical Center, Murray, UT, USA fontaine.gabe@gmail.com. 2. Department of Pharmacy, Intermountain Medical Center, Murray, UT, USA. 3. Department of Medicine, Intermountain Medical Center, Murray, UT, USA; Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. 4. Department of Medical Informatics, Intermountain Healthcare, Salt Lake City, UT, USA.
Abstract
BACKGROUND: Although the rate of bleeding among patients with atrial fibrillation (AF) taking novel oral anticoagulants in randomized controlled trials is described, the rate of bleeding with "real-world" use is uncertain. METHODS: We conducted a retrospective electronic medical record interrogation and subsequent chart review among patients within Intermountain Healthcare between October 2010 and November 2012. Patients were included if they had a diagnosis of AF and were receiving eitherdabigatran or rivaroxaban. Rates of major bleeding were calculated. RESULTS: Among 2579 patients, 13 (0.5%) experienced major bleeding (95% confidence interval [CI] 0.23-0.77), 5 (0.19%) experienced intracranial hemorrhage (95% CI 0.02-0.36), and 2 (0.08%) experienced fatal bleeding. Of the 13 patients experiencing a major bleed, 8 (61.5%) would have been excluded from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) andRivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) clinical trials. CONCLUSION: We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran orrivaroxaban.
RCT Entities:
BACKGROUND: Although the rate of bleeding among patients with atrial fibrillation (AF) taking novel oral anticoagulants in randomized controlled trials is described, the rate of bleeding with "real-world" use is uncertain. METHODS: We conducted a retrospective electronic medical record interrogation and subsequent chart review among patients within Intermountain Healthcare between October 2010 and November 2012. Patients were included if they had a diagnosis of AF and were receiving either dabigatran or rivaroxaban. Rates of major bleeding were calculated. RESULTS: Among 2579 patients, 13 (0.5%) experienced major bleeding (95% confidence interval [CI] 0.23-0.77), 5 (0.19%) experienced intracranial hemorrhage (95% CI 0.02-0.36), and 2 (0.08%) experienced fatal bleeding. Of the 13 patients experiencing a major bleed, 8 (61.5%) would have been excluded from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) clinical trials. CONCLUSION: We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban.
Authors: Maureen A Smythe; Michael J Forman; Elizabeth A Bertran; Janet L Hoffman; Jennifer L Priziola; John M Koerber Journal: J Thromb Thrombolysis Date: 2015-10 Impact factor: 2.300
Authors: Vincenzo Russo; Anna Rago; Riccardo Proietti; Federica Di Meo; Andrea Antonio Papa; Paolo Calabrò; Antonio D'Onofrio; Gerardo Nigro; Ahmed AlTurki Journal: Ther Adv Drug Saf Date: 2016-10-24
Authors: Karen D Burgos; Sarah E Sienko; Janet L Hoffman; John M Koerber; Maureen A Smythe Journal: Clin Appl Thromb Hemost Date: 2016-12-21 Impact factor: 2.389